Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® (PROTECT-1)
A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy
Sponsor: Sandoz
Listed as NCT01735175, this PHASE3 trial focuses on Breast Neoplasms and Chemotherapeutic Toxicity and remains completed. Sponsored by Sandoz, it has been updated 7 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Jul 2017 [monthly]
Completed PHASE3
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sandoz
- Sandoz GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aguascalientes, Mexico , Andhra Pradesh, India , Barnaul, Russia , Bashkortostan, Russia , Berdsk, Russia , Bucharest, Romania , Cherkasy, Ukraine , Chernivtsi, Ukraine , Delhi, India , Dnipropetrovsk, Ukraine and 27 more locations